Nicolas Leupin

1.7k total citations
29 papers, 730 citations indexed

About

Nicolas Leupin is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Nicolas Leupin has authored 29 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Hematology and 9 papers in Oncology. Recurrent topics in Nicolas Leupin's work include Chronic Lymphocytic Leukemia Research (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Nicolas Leupin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Nicolas Leupin collaborates with scholars based in Switzerland, United States and Belgium. Nicolas Leupin's co-authors include Hans de Haard, Torsten Dreier, Peter Ulrichts, E. Sally Ward, Erik Hofman, F. Javier Enriquez, Valérie Hanssens, Antonio Guglietta, Raimund J. Ober and Peter Verheesen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nicolas Leupin

28 papers receiving 711 citations

Peers

Countries citing papers authored by Nicolas Leupin

Since Specialization

Citations

This map shows the geographic impact of Nicolas Leupin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Leupin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Leupin more than expected).

Fields of papers citing papers by Nicolas Leupin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Leupin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Leupin. The network helps show where Nicolas Leupin may publish in the future.

Co-authorship network of co-authors of Nicolas Leupin

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Leupin. A scholar is included among the top collaborators of Nicolas Leupin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Leupin. Nicolas Leupin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma 2024 ·SHILAP Revista de lepidopterología ·Stefan Knop, (unknown), Norbert Grząśko, (unknown), Karolin Trautmann‐Grill, (unknown), Angelo Vacca, Cyrus Khandanpour, Barbara Gamberi, Luděk Pour, (unknown), Michael T. Stumpp, (unknown), Keith M. Dawson, Christof Zitt, Philippe Legenne, Vaia Stavropoulou, Martin F. Fey, Nicolas Leupin, Hartmut Goldschmidt	4
2	A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab 2022 ·JCO Precision Oncology ·Stefanie Fischer, Thorsten Oliver Götze, Aurelius Omlin, Richard D. Baird, Keith M. Dawson, Christof Zitt, (unknown), (unknown), Ulrike Fiedler, Simone Jeger, Samson Fung, Philippe Legenne, Nicolas Leupin, Andreas Schneeweiß, Carlo Fremd	5
3	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia 2019 ·Blood ·Adrian C. Newland, Blanca Sánchez‐González, László Rejtő, Miklós Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans de Haard, Nicolas Leupin, David J. Kuter	9
4	Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans 2018 ·Journal of Clinical Investigation ·Peter Ulrichts, Antonio Guglietta, Torsten Dreier, (unknown), Valérie Hanssens, Erik Hofman, (unknown), Peter Verheesen, (unknown), (unknown), F. Javier Enriquez, (unknown), Raimund J. Ober, E. Sally Ward, Hans de Haard, Nicolas Leupin	251
5	Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial 2018 ·Blood ·Adrian F. Ochsenbein, Carsten Riether, Ulrike Bacher, Rouven Müller, Sabine Höpner, Yara Banz, Magdalena Hinterbrandner, Mario Bargetzi, Markus G. Manz, Luc Van Rompaey, Mahan Moshir, (unknown), Domenica Gandini, (unknown), Anna Hultberg, Samson Fung, Hans de Haard, Nicolas Leupin, Thomas Pabst	16
6	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies 2017 ·Clinical Cancer Research ·Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean‐Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean‐Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada	47
7	Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34+ AML Stem and Progenitor Cells in Vitro and In Vivo 2017 ·Blood ·Magdalena Hinterbrandner, (unknown), (unknown), Thomas Pabst, Luc Van Rompaey, Nicolas Leupin, Hans de Haard, Adrian F. Ochsenbein, Carsten Riether	5
8	Argx-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such As Primary Immune Thrombocytopenia 2016 ·Blood ·Peter Ulrichts, (unknown), Torsten Dreier, Hans de Haard, Nicolas Leupin	4
9	Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Nizar J. Bahlis, Alessandro Corso, Lars‐Olof Mügge, Zhixiang Shen, P. Desjardins, A.-M. Stoppa, O. Decaux, Thierry de Revel, Miquel Granell, Gérald Marit, Hareth Nahi, H Demuynck, Shang‐Yi Huang, Supratik Basu, Annette Ervin‐Haynes, Nicolas Leupin, J Marek, (unknown), Thierry Façon	2
10	Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02) 2010 ·Leukemia & lymphoma ·Nicolas Leupin, Jan C. Schuller, Max Solenthaler, Dominik Heim, Alicia Rovó, (unknown), Michael Gregor, Mario Bargetzi, Peter Brauchli, Andreas Himmelmann, Silvia Hanselmann, (unknown)	6
11	A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials 2009 ·Contemporary Clinical Trials ·Jan C. Schuller, Michael Mayer, Doris Lanz, Shu‐Fang Hsu Schmitz, Peter Brauchli, Nicolas Leupin	2
12	Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasis 2009 ·Scandinavian Journal of Infectious Diseases ·(unknown), (unknown), Nicolas Leupin, Rémy Boscacci, Arthur Zimmermann, Norbert Müller, Christoph A. Fux	6
13	Lymphom der Prostata – Diagnose auf den „zweiten Stich“ 2008 ·Medizinische Klinik ·(unknown), (unknown), (unknown), Nicolas Leupin, Cyrill A. Rentsch, (unknown), Ulrich Bürgi, U Schiemann	0
14	The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells 2007 ·Journal of Leukocyte Biology ·Mattia Rizzi, Mario P. Tschan, Christian Britschgi, Adrian Britschgi, Barbara Hügli, Tobias Grob, Nicolas Leupin, Beatrice U. Mueller, Hans‐Uwe Simon, Andrew Ziemiecki, Bruce E. Torbett, Martin F. Fey, Andreas Tobler	43
15	The Combination of 2-CDA and Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL): A Prospective Multicenter Phase II Trial (SAKK 34/02). 2007 ·Blood ·Nicolas Leupin, Jan C. Schuller, Max Solenthaler, André Tichelli, Aloïs Gratwohl, (unknown), Mario Bargetzi, Andreas Himmelmann, (unknown), (unknown)	1
16	Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines 2006 ·British Journal of Haematology ·Nicolas Leupin, Alexandre Kuhn, Barbara Hügli, Tobias Grob, Rolf Jaggi, Andreas Tobler, Mauro Delorenzi, Martin F. Fey	9
17	p73 Status in B-cell Chronic Lymphocytic Leukaemia 2004 ·Leukemia & lymphoma ·Nicolas Leupin, Alexander U. Lüthi, Urban Novak, Tobias Grob, Barbara Hügli, H.U. Graber, Martin F. Fey, Andreas Tobler	22
18	Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL) 2003 ·British Journal of Haematology ·Nicolas Leupin, Bruno Cenni, Urban Novak, (unknown), H.U. Graber, Andreas Tobler, Martin F. Fey	37
19	Acute Radiation Colitis in Patients Treated With Short-Term Preoperative Radiotherapy for Rectal Cancer 2002 ·The American Journal of Surgical Pathology ·Nicolas Leupin, Jürgen Curschmann, (unknown), Christoph A. Maurer, Jean A. Laissue, Luca Mazzucchelli	27
20	Interaction of fungal spores with the lungs: Distribution and retention of inhaled puffball (Calvatia excipuliformis) spores 2000 ·Journal of Allergy and Clinical Immunology ·Marianne Geiser, Nicolas Leupin, (unknown), Vinzenz Im Hof, Peter Gehr	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact